Philips Medical Systems will showcase a mobile 1.5-tesla MRI scannercapable of traveling fully ramped up, according to the Shelton,CT, company. The vendor's Gyroscan ACS-NT Mobile unit builds onthe compactness of the NT line and solves many of the
Philips Medical Systems will showcase a mobile 1.5-tesla MRI scannercapable of traveling fully ramped up, according to the Shelton,CT, company. The vendor's Gyroscan ACS-NT Mobile unit builds onthe compactness of the NT line and solves many of the problemsfacing 1.5-tesla mobile imaging, according to Chris Farr, directorof marketing for MRI (SCAN 9/27/95).
In other MRI developments, Philips has adopted a low-cost arrayprocessor to produce a value-conscious edition of its MRI scanners.The 0.5-tesla Gyroscan-NT Lite carries a $800,000 list price.The entry point for the 1-tesla Gyroscan-NT Lite is about $1 million,according to Farr.
Philips is revamping its CT line, renaming all its scanners TomoscanAV (advanced volumetric), according to Marc Lawrence, North Americamarketing director for CT. The AV systems will be based on severalnew CT x-ray tubes using Philips' unique MRC liquid-metal technology.At the top end, MRC 201 is a 6.2-million-heat-unit (MHU) tubewith a 1.2 MHU per minute heat dissipation rate. MRC 160 is a3.5-MHU tube. All AV scanners can be upgraded to other systemsin the series, Lawrence said.
In ultrasound, the Philips/Hewlett-Packard ultrasound joint collaborationwill introduce enhancements to the SonoDiagnost 800. The new SD800 Advanced Value Platform features Color Velocity Imaging, Philips'time-domain vascular imaging technique. CVI-Angio is the time-domainequivalent of power Doppler techniques and CVI-Green Tag is anoption that colorizes selected velocities to determine areas ofhighest vascular flow.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.